![Walter P. Carney](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bruce Booth | M | 49 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | - |
Brian E. Ward | M | 71 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 6 years |
Michael T. Stocum | M | 58 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | - |
Robert Epstein | M | 58 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 4 years |
John Green | M | 43 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 1 years |
Paul Cleveland | M | 67 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | - |
Stephen Kraus | M | 47 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 12 years |
Dion Madsen | M | 56 |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 5 years |
Bradley W. Layton | M | - |
Thomas Jefferson University
| 3 years |
Alex de Winter | M | - |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | - |
Edward F. Smith | M | 70 |
Thomas Jefferson University
| 4 years |
Gary Palmer | M | - |
On-Q-ity, Inc.
![]() On-Q-ity, Inc. Medical/Nursing ServicesHealth Services On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships. | 2 years |
Albert D. Janerich | M | - |
Thomas Jefferson University
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 13 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Walter P. Carney
- Personal Network